Regulators of the immune checkpoint represent some of the most promising targets for immunotherapy. R&D Systems offers the widest selection of checkpoint proteins, all assessed for bioactivity and held to rigorous specifications that must be matched for each lot of protein made. The proteins include a selection of different tags and species, including Cynomolgus, allowing for maximum experimental flexibility. Our selection ranges from traditional targets such as PD-L1 and CTLA4, to next generation targets such as the Butyrophilins and LILRA/B Receptors.
This group contains some of the most targeted checkpoint proteins, including PD-1, PD-L1, and CTLA4.
Inhibitory leukocyte immunoglobulin-like receptors are increasingly recognized for putative roles in immune checkpoint and tumor promoters.
Butyrophilins have similar structure to the B7 family and are promising new checkpoint targets.
Including TIGIT and CD155/PVR, modulators of T Cell and NK cell activity and important immunotherapy targets.
Fc receptors bind antibodies where they regulate the immune response and the antibody pharmacokinetics.
Use our immunoassays and kits to measure cytokine secretion, proliferation, and cytotoxicity to ensure T cells are functioning as expected.
An enzyme in the metabolic pathway, IDO is also an immunosuppressive enzyme and checkpoint target. Bioactive proteins, antibodies, small molecule inhibitors, and more.
Expressed by a range of immune cell types, most members of the SLAM family can interact homotypically and may be immune activators or suppressors.
LAIR1 is a collagen-binding partner and a suppressor of T cell proliferation and activation.
A subset of this large family include immune checkpoint targets such CD40 , GITR, and HVEM.
Proteins including LAG-3, DPPIV, certain Integrins, and others are current targets of immune checkpoint research.